Viz.ai’s Intelligent Care Coordination Platform Data Highlight Impact in Real-World Settings

February 14, 2022—Viz.ai recently announced the presentation of data at the American Heart Association’s International Stroke Conference that provide insight into real-world use of their intelligent care coordination platform for stroke care.

According to the company, three poster sessions and one abstract presented data that conclude there is a positive impact to workflow and patient care from the use of multiple Viz Platform modules, including Viz LVO (for large vessel occlusion) and Viz ICH (for intracranial hemorrhage).

In the first poster session, Figurelle et al offered real-world data from the University of California at San Diego that demonstrated implementation of Viz.ai’s stroke platforms reduced the door-to-groin time by 41 minutes for LVO patients arriving directly to a comprehensive stroke center (CSC).

Then, Arminian et al highlighted the accuracy of the Viz ICH module at their CSC at Ohio State University, Wexner. Using the Viz.ai modular, radiologists were able to detect 82 of 83 ICH cases within the study period.

Finally, data from Mount Sinai Hospital further validated the impact these modules can have on real-world settings, noted Viz.ai. In a poster session, Matsoukas et al presented data from a study of 1,822 CTA scans demonstrating detection rates of 100% and 93% for internal carotid artery terminus (ICA-T) and M1 occlusions, respectively.

Viz.ai highlighted part of the authors’ conclusion in their press release: “In this work, the diagnostic accuracy of Viz LVO was tested in real life and real time across one of the to-date largest prospective consecutive cohorts, in a multiple-tiered healthcare system. Viz LVO is a promising AI-driven software that can reliably detect ICA-T and M1 LVOs with impressive NPV, sensitivity, and overall accuracy. It is a useful adjunct in triaging patients with a LVO stroke at varying levels of stroke centers.”

And in an abstract from the same center, Viz ICH was reported to have an overall accuracy of 99% among the 682 real-world patients studied.

Viz LVO, Viz ICH, and Viz CTP (used to analyze CT perfusion images) computer-aided triage and notification software all have received FDA clearance. In 2021, Viz.ai also received FDA clearance for their Viz PE and Viz Aortic platforms.